A phase II study of crisnatol mesylate in patients with ovarian carcinoma.

Smalley, R V; Goldstein, D; Bulkowski, D; Hannon, C; Buchler, D; Knudsen, C; Tuttle, R L

Smalley, R V; Goldstein, D; Bulkowski, D; Hannon, C; Buchler, D; Knudsen, C; Tuttle, R L.

Afiliación

Smalley RV; Clinical Cancer Center, University of Wisconsin.

Invest New Drugs ; 10(2): 107-12, 1992 Jul.

Article en En | MEDLINE | ID: mdl-1500264

RESUMEN

Fourteen patients with advanced ovarian cancer received a 72 hour infusion of a new DNA intercalator, crisnatol mesylate, administered intravenously. There was no evidence of antitumor efficacy. A syndrome of nausea and vomiting associated with vertigo, dizziness and ataxia was observed in nearly all patients. Two of the patients developed severe CNS toxicity manifested in one by a grand-mal seizure and in the other by peripheral neuropathy. Further explorations into the potential efficacy of crisnatol mesylate administered intraperitoneally are underway.

Asunto(s)

Antineoplásicos/uso terapéutico; Carcinoma/tratamiento farmacológico; Crisenos/uso terapéutico; Neoplasias Ováricas/tratamiento farmacológico; Glicoles de Propileno/uso terapéutico; Anciano; Anciano de 80 o más Años; Antígenos de Carbohidratos Asociados a Tumores/efectos de los fármacos; Carcinoma/inmunología; Esquema de Medicación; Evaluación de Medicamentos; Femenino; Humanos; Persona de Mediana Edad; Neoplasias Ováricas/inmunología; Resultado del Tratamiento

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Glicoles de Propileno / Carcinoma / Crisenos / Antineoplásicos Límite: Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Invest New Drugs Año: 1992 Tipo del documento: Article Pais de publicación: Estados Unidos

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links